Table of contents

Inflammatory bowel disease

• Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers

  (2 September, 2010)

  Carol L Roberts, Åsa V Keita, Sylvia H Duncan, Niamh O'Kennedy, Johan D Söderholm, Jonathan M Rhodes, Barry J Campbell
• Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy (24 June, 2010)

  C Loras, J P Gisbert, M Mínguez, O Merino, L Bujanda, C Saro, E Domenech, J Barrio, M Andreu, I Ordás, L Vida, G Bastida, F González-Huix, M Piqueras, D Ginard, X Calvet, A Gutiérrez, A Abad, M Torres, J Panés, M Chaparro, I Pascual, M Rodriguez-Carballeira, F Fernández-Bañares, J M Viver, M Esteve, for the REPENTINA study, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group
• T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c⁺ dendritic cells

  (23 August, 2010)

  Claudia Hofmann, Nadja Dunger, Nicole Grunwald, Günter J Hämmerling, Petra Hoffmann, Jürgen Schölmerich, Werner Falk, Florian Obermeier
• Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion

  (29 June, 2010)

  Nathalie Rolhion, Nicolas Barnich, Marie-Agnès Bringer, Anne-Lise Glasser, Julien Ranc, Xavier Hébuterne, Paul Hofman, Arlette Darfeuille-Michaud
• Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy (29 June, 2010)

  Harry Sokol, Philippe Seksik, Fabrice Carrat, Isabelle Nion-Larmurier, Ariane Vienne, Laurent Beaugerie, Jacques Cosnes